Importantly, we observed that applying VLDP of less than 5 IU/ml could enhance FoxP3 selectively in Treg compared to CD8+, CD4+CD25–CD127+/– and CD4+CD25+CD127+ effector T cells from the blood and liver of patients with AILD. This evidence concerns the gene CD4 and angioimmunoblastic T-cell lymphoma.